|
Oncology Competitive Intelligence Leaders
Executive Summary: ONCrg analyst Patrick Nygren previews the highest-impact clinical presentations across hematologic malignancies at ASH 2025, covering CLL, multiple myeloma, NHL, and AML, with a focus on practice-changing phase 3 readouts and early-stage combination signals.
Medical Conference Coverage EHA: June 11-14, 2026 WCLC: September 12-15, 2026 ESMO: October 23-27, 2026 SNO: November 12-15, 2026 SABCS: December 8-11, 2026 ASH: December 12-15, 2026 ASCO GU: February 11-13, 2027 ELCC: March 17-20, 2027 SGO: March 19-22, 2027 AACR: April 2-7, 2027 ASCO: June 4-8, 2027 ICML: June 15-19, 2027 Antibody-Drug Conjugates (ADCs) […]
Excerpt from Custom Post Type Indication: NHL
Excerpt from Custom Post Type Indication: MPNs
Excerpt from Custom Post Type Indication: MM
Excerpt from Custom Post Type Indication: MDS
Excerpt from Custom Post Type Indication: CLL
Excerpt from Custom Post Type Indication: AML
Excerpt from Custom Post Type Indication: ALL
Excerpt from Custom Post Type Indication: Cell Therapies